FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090947041> ?p ?o ?g. }

• W2090947041 endingPage "457" @default.
• W2090947041 startingPage "446" @default.
• W2090947041 abstract "Patients with marginal venous conduit, poor arterial runoff, and prior failed bypass grafts are at high risk for infrainguinal graft occlusion and limb loss. We sought to evaluate the effects of anticoagulation therapy after autogenous vein infrainguinal revascularization on duration of patency, limb salvage rates, and complication rates in this subset of patients.This randomized prospective trial was performed in a university tertiary care hospital and in a Veterans Affairs Hospital. Fifty-six patients who were at high risk for graft failure were randomized to receive aspirin (24 patients, 27 bypass grafts) or aspirin and warfarin (WAR; 32 patients, 37 bypass grafts). All patients received 325 mg of aspirin each day, and the patients who were randomized to warfarin underwent anticoagulation therapy with heparin immediately after surgery and then were started on warfarin therapy to maintain an international normalized ratio between 2 and 3. Perioperative blood transfusions and complications were compared with the Student t test or with the chi2 test. Graft patency rates, limb salvage rates, and survival rates were compared with the Kaplan-Meier method and the log-rank test.Sixty-one of the 64 bypass grafts were performed for rest pain or tissue loss, and 3 were performed for short-distance claudication. There were no differences between the groups in ages, indications, bypass graft types, risk classifications (ie, conduit, runoff, or graft failure), or comorbid conditions (except diabetes mellitus). The cumulative 5-year survival rate was similar between the groups. The incidence rate of postoperative hematoma (32% vs 3.7%; P = .004) was greater in the WAR group, but no differences were seen between the WAR group and the aspirin group in the number of packed red blood cells transfused, in the incidence rate of overall nonhemorrhagic wound complications, or in the overall complication rate (62% vs 52%). The immediate postoperative primary graft patency rates (97.3% vs 85.2%) and limb salvage rates (100% vs 88.9%) were higher in the WAR group as compared with the aspirin group. Furthermore, the cumulative 3-year primary, primary assisted, and secondary patency rates were significantly greater in the WAR group versus the aspirin group (74% vs 51%, P = .04; 77% vs 56%, P = .05; 81% vs 56%, P = .02) and cumulative limb salvage rates were higher in the WAR group (81% vs 31%, P = .01).Perioperative anticoagulation therapy with heparin increases the incidence rate of wound hematomas, but long-term anticoagulation therapy with warfarin improves the patency rate of autogenous vein infrainguinal bypass grafts and the limb salvage rate for patients at high risk for graft failure." @default.
• W2090947041 created "2016-06-24" @default.
• W2090947041 creator A5014785844 @default.
• W2090947041 creator A5016080958 @default.
• W2090947041 creator A5031567539 @default.
• W2090947041 creator A5040062674 @default.
• W2090947041 creator A5051803297 @default.
• W2090947041 creator A5070756295 @default.
• W2090947041 creator A5073397231 @default.
• W2090947041 date "1998-09-01" @default.
• W2090947041 modified "2023-10-13" @default.
• W2090947041 title "Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure" @default.
• W2090947041 cites W1970552670 @default.
• W2090947041 cites W1987299194 @default.
• W2090947041 cites W1992473166 @default.
• W2090947041 cites W1992546971 @default.
• W2090947041 cites W1994894525 @default.
• W2090947041 cites W2003103658 @default.
• W2090947041 cites W2009029991 @default.
• W2090947041 cites W2011570102 @default.
• W2090947041 cites W2022395232 @default.
• W2090947041 cites W2035956275 @default.
• W2090947041 cites W2043517681 @default.
• W2090947041 cites W2044828433 @default.
• W2090947041 cites W2047539287 @default.
• W2090947041 cites W2057735129 @default.
• W2090947041 cites W2063857463 @default.
• W2090947041 cites W2075433782 @default.
• W2090947041 cites W2078966363 @default.
• W2090947041 cites W2089912368 @default.
• W2090947041 cites W2094416797 @default.
• W2090947041 cites W2123096133 @default.
• W2090947041 cites W2130268358 @default.
• W2090947041 cites W2153281494 @default.
• W2090947041 cites W2314922794 @default.
• W2090947041 cites W2419447135 @default.
• W2090947041 cites W4231595983 @default.
• W2090947041 cites W4239471829 @default.
• W2090947041 cites W4252241269 @default.
• W2090947041 cites W4299399588 @default.
• W2090947041 cites W4300741295 @default.
• W2090947041 doi "https://doi.org/10.1016/s0741-5214(98)70130-2" @default.
• W2090947041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9737454" @default.
• W2090947041 hasPublicationYear "1998" @default.
• W2090947041 type Work @default.
• W2090947041 sameAs 2090947041 @default.
• W2090947041 citedByCount "161" @default.
• W2090947041 countsByYear W20909470412012 @default.
• W2090947041 countsByYear W20909470412013 @default.
• W2090947041 countsByYear W20909470412014 @default.
• W2090947041 countsByYear W20909470412015 @default.
• W2090947041 countsByYear W20909470412016 @default.
• W2090947041 countsByYear W20909470412017 @default.
• W2090947041 countsByYear W20909470412018 @default.
• W2090947041 countsByYear W20909470412019 @default.
• W2090947041 countsByYear W20909470412020 @default.
• W2090947041 countsByYear W20909470412021 @default.
• W2090947041 countsByYear W20909470412022 @default.
• W2090947041 countsByYear W20909470412023 @default.
• W2090947041 crossrefType "journal-article" @default.
• W2090947041 hasAuthorship W2090947041A5014785844 @default.
• W2090947041 hasAuthorship W2090947041A5016080958 @default.
• W2090947041 hasAuthorship W2090947041A5031567539 @default.
• W2090947041 hasAuthorship W2090947041A5040062674 @default.
• W2090947041 hasAuthorship W2090947041A5051803297 @default.
• W2090947041 hasAuthorship W2090947041A5070756295 @default.
• W2090947041 hasAuthorship W2090947041A5073397231 @default.
• W2090947041 hasBestOaLocation W20909470411 @default.
• W2090947041 hasConcept C126322002 @default.
• W2090947041 hasConcept C141071460 @default.
• W2090947041 hasConcept C168563851 @default.
• W2090947041 hasConcept C2776301958 @default.
• W2090947041 hasConcept C2777466421 @default.
• W2090947041 hasConcept C2777628954 @default.
• W2090947041 hasConcept C2778963770 @default.
• W2090947041 hasConcept C2779161974 @default.
• W2090947041 hasConcept C2779464278 @default.
• W2090947041 hasConcept C3018348675 @default.
• W2090947041 hasConcept C31174226 @default.
• W2090947041 hasConcept C42219234 @default.
• W2090947041 hasConcept C500558357 @default.
• W2090947041 hasConcept C71924100 @default.
• W2090947041 hasConceptScore W2090947041C126322002 @default.
• W2090947041 hasConceptScore W2090947041C141071460 @default.
• W2090947041 hasConceptScore W2090947041C168563851 @default.
• W2090947041 hasConceptScore W2090947041C2776301958 @default.
• W2090947041 hasConceptScore W2090947041C2777466421 @default.
• W2090947041 hasConceptScore W2090947041C2777628954 @default.
• W2090947041 hasConceptScore W2090947041C2778963770 @default.
• W2090947041 hasConceptScore W2090947041C2779161974 @default.
• W2090947041 hasConceptScore W2090947041C2779464278 @default.
• W2090947041 hasConceptScore W2090947041C3018348675 @default.
• W2090947041 hasConceptScore W2090947041C31174226 @default.
• W2090947041 hasConceptScore W2090947041C42219234 @default.
• W2090947041 hasConceptScore W2090947041C500558357 @default.
• W2090947041 hasConceptScore W2090947041C71924100 @default.
• W2090947041 hasIssue "3" @default.
• W2090947041 hasLocation W20909470411 @default.

• next